免疫治疗时代同步转移性肾细胞癌 upfront 减瘤性肾切除术的全国真实世界评估
该全国性历史队列研究纳入2018–2020年荷兰872例同步转移性肾细胞癌患者,采用倾向性评分IPTW比较upfront减瘤性肾切除术(uCN)与仅系统治疗的总生存。IO队列中uCN+IO组中位OS 33个月 vs IO±dCN组24个月(HR 0.62,95%CI 0.40–0.97);TKI队列无显著差异(19 vs 17个月,HR 0.76,95%CI 0.52–1.12)。
要点
- IO队列中uCN与更优OS相关(中位33 vs 24个月,HR 0.62)
- TKI队列中uCN未显示显著OS获益(HR 0.76,95%CI 0.52–1.12)
- uCN组预后因素更有利,存在残余混杂,需RCT验证
核心结论
- 在缺乏RCT的情况下,IO时代预后因素良好的mRCC患者可能偏好uCN。
研究设计与样本
- 荷兰全国性历史队列研究,纳入2018–2020年诊断的同步mRCC患者872例,接受IO或TKI治疗,采用倾向性评分IPTW调整预后差异。
主要发现
- IO队列:uCN+IO组63例,IO±dCN组370例;IPTW调整后中位OS 33个月 vs 24个月(HR 0.62,95%CI 0.40–0.97)。
- TKI队列:uCN+TKI组67例,TKI±dCN组372例;中位OS 19个月 vs 17个月(HR 0.76,95%CI 0.52–1.12),无显著差异。
- uCN治疗组较起始系统治疗组具有更有利的预后因素。
临床怎么用
- 对预后因素良好的同步mRCC患者,在IO时代可考虑upfront减瘤性肾切除术。
- TKI治疗背景下uCN的OS获益不显著,决策需个体化。
局限性
- 观察性研究设计,存在残余混杂风险。
- 缺乏随机对照试验证据,需RCT进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Since the advent of targeted therapy, deferred cytoreductive nephrectomy (dCN) has been offered to patients with metastatic renal cell carcinoma (mRCC) who respond to systemic therapy. Transition to the immunotherapy (IO) era necessitates a re-evaluation of the role of upfront CN (uCN) in mRCC management. Our aim was to determine whether uCN improves overall survival (OS) in patients with mRCC receiving IO in comparison to tyrosine kinase inhibitor (TKI) therapy. METHODS: This nationwide historical cohort study included patients with synchronous mRCC diagnosed in the Netherlands between 2018 and 2020 who were treated with IO or TKI agents. We used propensity score-based inverse probability of treatment weighting (IPTW) to adjust for prognostic differences in Kaplan-Meier and Cox regression analyses. OS was compared for patients with versus without uCN. Analyses were stratified for IO and TKI therapy. KEY FINDINGS AND LIMITATIONS: Of 872 patients, 433 received IO (63 uCN + IO, 370 IO ± dCN) and 439 received TKI (67 uCN + TKI, 372 TKI ± dCN) therapy. The uCN treatment arms had more favourable prognostic factors than those starting with systemic therapy. In the IO cohort, the IPTW-adjusted median OS was 33 mo for uCN + IO versus 24 mo for IO ± dCN (hazard ratio [HR] 0.62, 95% confidence interval [CI] 0.40-0.97). There was no significant difference in median OS in the TKI cohort (19 mo for uCN + TKI versus 17 mo for TKI ± dCN; HR 0.76, 95% CI 0.52-1.12). Limitations include the observational nature of the study and the risk of residual confounding. CONCLUSIONS AND CLINICAL IMPLICATIONS: In the absence of randomised controlled trials (RCTs), our results indicate a preference for uCN in patients with mRCC with favourable prognostic factors in the IO era. Owing to the risk of residual confounding, strong evidence from RCTs is needed.
引用
- Yildirim H, Aben KKH, Bijlsma MJ, et al. A Nationwide Real-world Evaluation of Upfront Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma in the Immunotherapy Era. Eur Urol Oncol. 2025. PMID: 40221280. doi:10.1016/j.euo.2025.02.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。